Pay in 4 interest-free payments of $6.03 Learn more
Ships within 48 hours · Estimated delivery Aug 10 - Aug 15
Symptom monitoring: Fatigue, numbness or cognitive problems should improve with treatment
Not intended as a medical, cosmetic, or household product
99% High Purity Product Discreet and Secure Shipping Certified Products For research purposes only
Opening Hours Monday 9:00am - 6:00pm Tuesday9:00am - 6:00pm Wednesday9:00am - 6:00pm Thursday9:00am - 6:00pm Friday 9:00am - 6:00pm Saturday9:00am - 1:00pm SundayClosed
At the molecular level, 5-amino-1MQ functions as a competitive inhibitor of NNMT, demonstrating remarkable potency with an IC of 1.2 0.1 M under standard assay conditions (50 M SAM, 100 M nicotinic acid). This represents a dramatic 10-fold improvement over the parent compound 1-methylquinolinium, achieved through strategic amino group substitution that enhances binding affinity to the NNMT active site. The compound's mechanism centers on preventing the methylation of nicotinamide to 1-methylnicotinamide (1-MNA), thereby preserving nicotinamide for recycling back to NAD+ through the salvage pathway. This intervention effectively blocks what researchers have termed the "NNMT metabolic drain" a process that simultaneously depletes NAD+ precursors and consumes cellular methylation capacity
This timeline matches B12 pharmacokinetics: intramuscular methylcobalamin reaches peak serum concentration at 8-12 hours, but tissue saturation (particularly in the liver and nervous system) occurs over 48-72 hours as the vitamin is transported into cells and converted to active coenzyme forms (Andrs et al., 2018)
US$ 22.46
US$ 22.34
US$ 21.00
